Advertisement

Current Rheumatology Reports

, Volume 3, Issue 5, pp 379–386 | Cite as

Juvenile dermatomyositis: The association of the TNFα-308A Allele and disease chronicity

  • Lauren M. Pachman
  • Tamara O. Fedczyna
  • Toula S. Lechman
  • Jennica Lutz
Article

Abstract

Little is known concerning factors associated with the outcome of juvenile dermatomyositis (JDM), which can be variable and lethal. Previous work has documented that the association of DQA1*0501 with JDM is higher than in control groups and that the first symptoms (rash and weakness) of JDM appear to follow evidence of an infectious process—most frequently upper respiratory in nature. Preliminary data show that a long period of symptoms being left untreated before starting therapy and the TNFa-308A allele are associated with prolonged JDM symptoms requiring ≥36 months of immunosuppressive therapy. A short duration of untreated disease is associated with a relative increase in CD8+ T cells and CD56+ natural killer (NK) cells in the untreated JDM muscle biopsy compared with a longer duration of untreated disease. The TNFa-308A allele is overrepresented in white children with JDM. In addition, it is associated with pathologic calcifications, increased production of TNFa by peripheral blood mononuclear cells in vitro and JDM muscle fibers in vivo, and occlusion of capillaries, which may be mediated in part by elevated circulating levels of thrombospondin-1, a potent anti-angiogenic factor. We speculate that DQA1*0501 is associated with JDM susceptibility to an infectious process, eliciting and activating NK cells early in the disease course. We conclude that the TNFa-308A allele indicates directly (or is a surrogate marker of) children with JDM who produce higher concentrations of TNFa in response to this undefined inflammatory stimulus, as well as increased concentrations of TSP-1 with resultant small vessel occlusion, contributing to subsequent disease chronicity.

Keywords

Muscle Biopsy Brucellosis Dermatomyositis Idiopathic Inflammatory Myopathy Juvenile Dermatomyositis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Mendez E, Lipton RB, Dyer A, et al.: Incidence of juvenile dermatomyositis (JDM) in the USA: results from a NIAMS JDM Research Registry. Arthritis Rheum 1999, 43:679.Google Scholar
  2. 2.
    Pachman LM, Liotta-Davis MR, Hong DK, et al.: TNFa-308A allele in juvenile dermatomyositis—associations with increased TNFa production, disease duration, and pathological calcifications. Arthritis Rheum 2000, 43:2368–2377. Report of a genetic association with chronic disease in juvenile dermatomyositis.PubMedCrossRefGoogle Scholar
  3. 3.
    Bohan A, Peter JB: Polymyositis and dermatomyositis (parts 1 and 2). N Engl J Med 1975, 292:344–347; 403–407. Provides the classic criteria for case definition.PubMedCrossRefGoogle Scholar
  4. 4.
    Hernandez RJ, Sullivan DB, Chenevert TL: MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings. AJR 1993, 161:359–366.PubMedGoogle Scholar
  5. 5.
    Pachman LM, Fedczyna TO, Lutz JL, et al.: Increased CD8+and CD56+ lymphocytes in untreated juvenile dermatomyositis (JDM) muscle biopsies (MBx) are associated with a short compared with a long disease duration. Arthritis Rheum 2000, 43:772.CrossRefGoogle Scholar
  6. 6.
    Love LA, Leff RL, Fraser DD, et al.: A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360–374.Google Scholar
  7. 7.
    Rider LG, Miller FW, Targoff IN, et al.: A broadened spectrum of juvenile myositis: myositis-specific autoantibodies in children. Arthritis Rheum 1994, 37:1534–1538.PubMedCrossRefGoogle Scholar
  8. 8.
    Rider LG, Miller FW: Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 1997, 23:619–655. A good review of classification and treatment of juvenile dermatomyositis.PubMedCrossRefGoogle Scholar
  9. 9.
    Feldman BM, Reichlin M, Laxer RM, et al.: Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol 1996, 23:1794–1797.PubMedGoogle Scholar
  10. 10.
    Roux S, Seelig HP, Meyer O: Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis [letter]. J Rheumatol 1998, 25:395–396.PubMedGoogle Scholar
  11. 11.
    Maugars YM, Berthelot JM, Abbas AA, et al.: Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996, 14:263–274.PubMedGoogle Scholar
  12. 12.
    Collison CH, Sinal SH, Jorizzo JL, Walker FO, Monu JU, Snyder J: Juvenile dermatomyositis and polymyositis: a follow-up study of long-term sequelae. South Med J 1998, 91:17–22.PubMedGoogle Scholar
  13. 13.
    Huber AM, Lang B, LeBlanc CM, et al.: Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000, 43:541–549. Good review of outcome studies.PubMedCrossRefGoogle Scholar
  14. 14.
    Eisenstein DM, Paller AS, Pachman LM: Juvenile dermatomyositis presenting with rash alone. Pediatrics 1997, 100:391–392.PubMedCrossRefGoogle Scholar
  15. 15.
    Spencer CH, Hanson V, Singsen BH, et al.: Course of treated juvenile dermatomyositis. J Pediatr 1984, 105:399–408.PubMedCrossRefGoogle Scholar
  16. 16.
    Bitnum S, Daeschner CW, Travis LB, Dodge WF, Hopps HC:Dermatomyositis. J Pediatr 1964, 64:101–131.PubMedCrossRefGoogle Scholar
  17. 17.
    Pachman LM, Jonasson O, Cannon RA, et al.: Increased frequency of HLA-B8 in patients with juvenile dermatomyositis. Lancet 1977, ii:567–568.CrossRefGoogle Scholar
  18. 18.
    Friedman JM, Pachman LM, Maryjowski ML, et al.:Immunogenetic studies of juvenile dermatomyositis: HLA antigens in patients and their families. Tissue Antigens 1983, 21:45–49.PubMedCrossRefGoogle Scholar
  19. 19.
    Friedman JM, Pachman LM, Maryjowski ML, et al.:Immunogenetic studies of juvenile dermatomyositis: HLADR antigen frequencies. Arthritis Rheum 1983, 26:214–216.PubMedCrossRefGoogle Scholar
  20. 20.
    Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al.: Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:1257–1266.PubMedGoogle Scholar
  21. 21.
    Vavrincova P, Havelka S, Cerna M, Stastny P: HLA class II alleles in juvenile dermatomyositis. J Rheumatol (Suppl) 1993, 37:17–18.Google Scholar
  22. 22.
    Rider LG, Shamim E, Okada S, et al.: Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. Arthritis Rheum 1999, 42:1285–1290.PubMedCrossRefGoogle Scholar
  23. 23.
    Shamim EA, Rider LG, Miller FW: Update on the genetics of the idiopathic inflammatory myopathies. Curr Opin Immunol 2000, 12:482–491. Good review on genetics of idiopathic inflammatory myopathy.Google Scholar
  24. 24.
    Reed AM, Picornell J, Harwood A, Kredich DW: Chimerism in children with dermatomyositis. Arthritis Rheum 2000, 43:S276.Google Scholar
  25. 25.
    Lambert NC, Evans PC, Hashizumi TL, et al.: Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: implications in autoimmunity. Arthritis Rheum 2000, 43:2005–2010.PubMedCrossRefGoogle Scholar
  26. 26.
    Reed AM, Pachman LM, Hayford JR, Ober C: Immunogenetic studies in families of children with juvenile dermatomyositis. J Rheumatol 1998, 25:1000–1002.PubMedGoogle Scholar
  27. 27.
    Wilson AG, diGiovine FS, Blakemore AIF, Duff GW: Single base polymorphism in the human tumor necrosis factor (TNFa) gene detected by NcoI restriction of PCR product. Hum Mol Genet 1992, 1:353.PubMedCrossRefGoogle Scholar
  28. 28.
    Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW:Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. PNAS (USA) 1997, 94:3195–3199.CrossRefGoogle Scholar
  29. 29.
    Andre C, Guillemin MC, Zhu J, et al.: The PML and PML/RAR alpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic. Exp Cell Res 1996, 229:253–260.PubMedCrossRefGoogle Scholar
  30. 30.
    Caballero A, Bravo MJ, Nieto A, et al.: TNFA promoter polymorphism and susceptibility to brucellosis. Clin Exp Immunol 2000, 121:480–483.PubMedCrossRefGoogle Scholar
  31. 31.
    Warzocha K, Ribeiro P, Bienvenu J, et al.: Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin’s lymphoma outcome. Blood 1998, 91:3574–3581.PubMedGoogle Scholar
  32. 32.
    Knuchel MC, Spira TJ, Neumann AU, et al.: Analysis of a biallelic polymorphism in the tumor necrosis factor alpha promoter and HIV type 1 disease progression. AIDS Res Hum Retrovir 1998, 14:305–309.PubMedCrossRefGoogle Scholar
  33. 33.
    Spriggs DRDSKDW: Genomic structure, induction, and production of TNF-alpha. Immunol Serol 1992, 56:3–34. Good review of control of TNFa production.Google Scholar
  34. 34.
    Obayashi H, Nakamura N, Fukui M, et al.: Influence of TNF microsatellite polymorphisms (TNFa) on age-at-onset of insulin-dependent diabetes mellitus. Hum Immunol 1999, 60:974–978.PubMedCrossRefGoogle Scholar
  35. 35.
    Bleeker JL, Meire VI, Declercq W, Van Aken EH:Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromusc Disord 1999, 9:239–246.CrossRefGoogle Scholar
  36. 36.
    Fedczyna TO, Lutz JL, Caliendo J, Pachman LM: Expression of TNFa in muscle fibers in biopsies (MBx) from untreated juvenile dermatomyositis (JDM) is associated with the TNFa-308A allele. Arthritis Rheum 2000, 43, 1255-S276.Google Scholar
  37. 37.
    Beutler B, van Huffel C: Unraveling function in the TNF ligand and receptor families. Science 1994, 264:667–668.PubMedCrossRefGoogle Scholar
  38. 38.
    Fiers W: Tumor necrosis factor: characterization at the molecular, cellular and in vivo level. FEBS Letters 1991, 285:199–212. Good review of the early concepts of TNF.PubMedCrossRefGoogle Scholar
  39. 39.
    Boehm U, Klamp T, Groot M, Howard RF: Cellular responses to IFN-g. Annu Rev Immunol 1997, 15:749–795.PubMedCrossRefGoogle Scholar
  40. 40.
    Tezak Z, Hoffman EP, Pachman LM: Expression profiling in untreated juvenile dermatomyositis. J Neurol 2001, In press.Google Scholar
  41. 41.
    Schluter D, Deckert M: Divergent role of tumor necrosis factor receptors in infectious diseases. Microb Infect 2000, 2:1285–1292. Good review of TNF receptors.CrossRefGoogle Scholar
  42. 42.
    Smyth MJ, Johnstone RW: Role of TNF in lymphocytemediated cytotoxicity. Microsc Res Tech 2000, 50:196–208. Good review of the mechanism of action of TNF.PubMedCrossRefGoogle Scholar
  43. 43.
    Rider LG, Ahmed A, Beausang L, et al.: Elevations of interleukin-1 receptor antagonist (IL1RA), sTNFR, sIL2R and IL-10 in juvenile idiopathic inflammatory myopathies (JIIM) suggest a role for monocyte/macrophage and B lymphocyte activation. Arthritis Rheum 1998, 41:S265.CrossRefGoogle Scholar
  44. 44.
    Pachman LM, Mendez E, Lou H, et al.: Parent report of antecedent illness and environmental factors before onset of juvenile dermatomyositis (JDM): NIAMS JDM research registry data. Arthritis Rheum 1999, 42:395.CrossRefGoogle Scholar
  45. 45.
    Pachman LM, Hayford JR, Hochberg MC, et al.: New-onset juvenile dermatomyositis: comparisons with a healthy cohort and children with juvenile rheumatoid arthritis. Arthritis Rheum 1997, 40:1526–1533. Case-control study documenting increased infection in the 3 months before the first definite symptom of juvenile dermatomyositis.PubMedCrossRefGoogle Scholar
  46. 46.
    Banker BQ, Victor M: Dermatomyositis (systemic angiopathy) of childhood. Medicine 1966, 45:261–289. First histologic description of juvenile dermatomyositis.PubMedCrossRefGoogle Scholar
  47. 47.
    Pachman LM, Lingen M, Caliendo J, Kinder J, Chen EH: Muscle biopsy findings in 38 untreated children with juvenile dermatomyositis (JDM): capillary occlusion is associated with the TNF2 allele. Arthritis Rheum 1999, 42:1994-S403.Google Scholar
  48. 48.
    Scott JP, Arroyave C: Activation of complement and coagulation in juvenile dermatomyositis. Arthritis Rheum 1987, 30:572–576.PubMedCrossRefGoogle Scholar
  49. 49.
    Koch AE, Szekanecz Z, Friedman J, et al.: Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis. Clin Immunol Immunopath 1998, 86:199–208.CrossRefGoogle Scholar
  50. 50.
    Roth JJ, Gahtan V, Brown JL, et al.: Thrombospondin-1 is elevated with both intimal hyperplasia and hypercholesterolemia. J Surg Res 1998, 74:11–16.PubMedCrossRefGoogle Scholar
  51. 51.
    Lutz JL, Fedczyna TO, Huwiler K, et al.: Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNFa-308A polymorphism in children with juvenile dermatomyositis (JDM). Arthritis Rheum 2000, 43, 652-S175.Google Scholar
  52. 52.
    Miller ML, Mendez E, Klein-Gitelman MS, Pachman LM:Experience with etanercept in chronic juvenile dermatomyositis (JDM). Arthritis Rheum 2000, 43:1883.CrossRefGoogle Scholar
  53. 53.
    Cambridge G, Ovadia E, Isenberg DA, et al.: Juvenile dermatomyositis: serial studies of circulating autoantibodies to a 56kD nuclear protein. Clin Exp Rheumatol 1994, 12:451–457.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Lauren M. Pachman
    • 1
  • Tamara O. Fedczyna
    • 1
  • Toula S. Lechman
    • 1
  • Jennica Lutz
    • 1
  1. 1.Division of Pediatric Immunology/RheumatologyNorthwestern University Medical School, The Children’s Memorial HospitalChicagoUSA

Personalised recommendations